News round-up by DDW’s Megan Thomas for 30 August – 3 September
DDW’s Megan Thomas has rounded up five stories in which studies, collaborations and trials pave the way towards treatments for a number of potentially fatal conditions.
1. NIH studies Covid-19 vaccine dose for people with autoimmune disease
The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.
2. SK bioscience and GSK start trial of Covid-19 vaccine
SK bioscience (SK) and GlaxoSmithKline (GSK) have initiated a Phase III clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase I/II results.
3. Novartis collaboration has potential to improve heart health in UK
Novartis and NHS England are to pioneer a population health management approach to address elevated LDL-C in patients with Atherosclerotic Cardiovascular Disease (ASCVD) across England.
4. Viagra can strongly suppress abnormal heart rhythms, finds study
Scientists from the University of Manchester have found that the drug Viagra, used to treat sexual impotence, can strongly suppress abnormal heart rhythms known as arrythmias in sheep.
5. Moderna submits initial data to FDA for Covid-19 vaccine booster
Moderna has initiated its submission to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. The company expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world shortly.
